Android app on Google Play

Streetinsider.com After-Hours Movers 1/29: (UIS) (AMZN) (PRXL) Higher; (VTUS) (KERX) (WBSN) Lower (more...)

January 29, 2013 6:03 PM EST Send to a Friend
Unisys Corp. (NYSE: UIS) 10% HIGHER; reported Q4 EPS of $2.27, $1.34 better than the analyst estimate of $0.93. Revenue for the quarter came in at $979 million versus the consensus estimate of $923.9 million.

Chesapeake Energy (NYSE: CHK) 10% HIGHER; Co-founder, Chief Executive Officer and President, Aubrey K. McClendon, has agreed to retire from the company on April 1, 2013.

Amazon.com, Inc. (NASDAQ: AMZN) 8% HIGHER; reported Q4 EPS of $0.21, $0.06 worse than the analyst estimate of $0.27. Revenue for the quarter rose 22$ to $21.27 billion versus the consensus estimate of $22.27 billion.

Ventrus Biosciences, Inc. (Nasdaq: VTUS) 8% LOWER; is concurrently offering to sell, subject to market and other conditions, (i) shares of its common stock in an underwritten public offering, and (ii) shares of its Series A Convertible Preferred Stock in a separate underwritten public offering.

Spansion Inc. (NYSE: CODE) 8% LOWER; reported Q4 EPS of $0.34, $0.02 worse than the analyst estimate of $0.36. Revenue for the quarter came in at $224 million versus the consensus estimate of $234.4 million.

Aspen Technology, Inc. (NASDAQ: AZPN) 5% HIGHER; reported Q2 EPS of $0.10, $0.05 better than the analyst estimate of $0.05. Revenue for the quarter came in at $77.3 million versus the consensus estimate of $67.97 million. Sees FY13 non-GAAP EPS of $0.28 - $0.33, versus the consensus of $0.26. FY13 revs expected to be $295 million to $302 million, compared with the consensus of $291.6 million.

ACE Ltd. (NYSE: ACE) 4% LOWER; reported Q4 EPS of $1.43, $0.15 better than the analyst estimate of $1.28. Revenue for the quarter came in at $0 versus the consensus estimate of $3.26 billion.

Dolby Laboratories Inc. (NYSE: DLB) 4% HIGHER; reported Q1 EPS of $0.50, $0.05 better than the analyst estimate of $0.45. Revenue for the quarter came in at $236.6 million versus the consensus estimate of $220.99 million. Dolby Laboratories Inc. sees Q2 2013 EPS of $0.68-0.75, versus the consensus of $0.75. Dolby Laboratories Inc. sees Q2 2013 revenue of $240-250 million, versus the consensus of $251.2 million. Dolby Laboratories Inc. sees FY2013 revenue of $910-950 million, versus the consensus of $918.5 million.

Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) 3% LOWER; commenced a $55 million underwritten public offering of shares of its common stock.

Websense, Inc. (NASDAQ: WBSN) 3% LOWER; reported Q4 EPS of $0.28, $0.05 worse than the analyst estimate of $0.33. Revenue for the quarter came in at $91.7 million versus the consensus estimate of $91.01 million. Sees Q113 EPS of $0.15-0.19, versus the consensus of $0.35. Websense, Inc. sees Q113 revenue of $84-87 million, versus the consensus of $90.24 million. Websense, Inc. sees FY2013 EPS of $0.78-0.93, versus the consensus of $1.54. Websense, Inc. sees FY2013 revenue of $351-361 million, versus the consensus of $367.40 million

Parexel International Corp (NASDAQ: PRXL) 3% HIGHER; reported Q2 EPS of $0.41, $0.08 better than the analyst estimate of $0.33. Revenue for the quarter came in at $422.1 million versus the consensus estimate of $419.78 million. Sees FY2013 EPS of $1.48-1.56, versus prior guidance of $1.36-1.43 and the consensus of $1.42. Parexel International Corp sees FY2013 revenue of $1.695-1.71 billion, versus prior guidance of $1.675-1.695 billion and the consensus of $1.689 billion.

Plantronics, Inc. (NYSE: PLT) 3% HIGHER; reported Q3 EPS of $0.73, $0.05 better than the analyst estimate of $0.68. Revenue for the quarter came in at $197.4 million versus the consensus estimate of $186.05 million. Plantronics, Inc. sees Q4 2013 EPS of $0.68-0.72, versus the consensus of $0.68.

Ryland Group, Inc. (NYSE: RYL) 3% HIGHER; reported Q4 EPS of $0.56, $0.07 better than the analyst estimate of $0.49. Revenue for the quarter came in at $440.1 million versus the consensus estimate of $401.5 million.

Starz (NASDAQ: STRZA) 2% HIGHER; SAC Capital Shows New 5.72% Stake.

Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) 2% LOWER; reported Q4 EPS of $0.04, $0.11 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $334 million versus the consensus estimate of $318.53 million. Vertex Pharmaceuticals, Inc. sees FY2013 revenue of $1.10-1.25 billion, versus the consensus of $1.16 billion




You May Also Be Interested In


Related Categories

Special Reports

Related Entities

SAC Capital, Steven A. Cohen, After-Hours Movers

Add Your Comment